ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Coronavirus vaccine set for testing, says startup backed by Singapore VC

Vickers Venture invests in U.K.'s Emergex as biotechs race to develop drug

Prisoners receive seasonal flu vaccination in Chile in March as the coronavirus outbreak spreads across the globe.    © Reuters

SINGAPORE -- As the new coronavirus spreads across the globe and devastates communities, companies are racing to develop a vaccine, with the U.K.'s Emergex becoming the latest to divert resources from other projects, including the development of a dengue fever vaccine, to work on COVID-19.

The startup expects to have a vaccine ready for testing within two months, Lim Xinhong, director and analyst at Singapore-based venture capital firm Vickers Venture Partners told DealStreetAsia. Vickers Venture is an investor in Emergex.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more